Clinical Trial

Assessing the Procalcitonin-guidance and Molecular-guided Diagnosis for Therapy of Severe Infections (the MODIFY Trial)

Study acronym: MODIFY
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated January 16, 2026 (before its estimated April 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
MODIFY is a randomized, open-labeled, and prospective study that will be conducted in multiple Intensive Care Units (ICUs) and departments of Internal Medicine across Greece. It aims to change the traditional approach for the management of severe infections by integrating the results of BCID2, Reveal Rapid AST, and PCT, to improve patients' outcomes. Early and precise identification of the underlying causative pathogen along with the fast acquisition of the antimicrobial sensitivity results may positively impact the uncontrolled antimicrobial prescription.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2023-06-09; most recent amendment 2026-01-15.
Status change: Recruiting → Active, Not Recruiting 2026-01-15
Status change: Not Yet Recruiting → Recruiting 2023-09-21
Trial Details
NCT Number NCT05909683
Lead Sponsor Hellenic Institute for the Study of Sepsis
Conditions Sepsis
Enrollment 190 participants
Start Date 2023-09-19
Primary Completion 2026-04-15 (estimated)
Study Completion 2026-04-15 (estimated)
Updated on ClinicalTrials.gov 2026-01-16